Last update July 31, 2018

Perindopril

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

Perindopril and its active metabolite perindoprilat are angiotensin converting enzyme inhibitors (ACEI) used in the treatment of hypertension and heart failure.
Oral administration every 12-24 hours.

It is excreted in breastmilk in clinically insignificant amounts (Anderson 2018, Lwin 2017).

Until there is more information about this drug in relation to breastfeeding, safer known alternatives are preferable.

Due to its possible renal toxicity in preterm infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015).

The protective role of breastfeeding against maternal hypertension has been proven (Park 2018).

Alternatives

  • Captopril ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Enalapril ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Perindopril is also known as


Perindopril in other languages or writings:

Group

Perindopril belongs to this group or family:

Tradenames

Main tradenames from several countries containing Perindopril in its composition:

List of 16 tradenames

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 65 - 75 %
Molecular weight 369 daltons
Protein Binding 10 - 20 %
VD 0.22 l/Kg
pKa 3.79 -
Tmax 3 - 4 hours
T½ 30 hours
M/P ratio 0.22 -

References

  1. Park S, Choi NK. Breastfeeding and Maternal Hypertension. Am J Hypertens. 2018 Abstract
  2. Anderson PO. Treating Hypertension During Breastfeeding. Breastfeed Med. 2018 Abstract
  3. Lwin EMP, Gerber C, Song Y, Leggett C, Ritchie U, Turner S, Garg S. A new LC-MS/MS bioanalytical method for perindopril and perindoprilat in human plasma and milk. Anal Bioanal Chem. 2017 Abstract
  4. Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015 Jan 20;144(2):73-9. Abstract
  5. AEMPS. Perindopril Ficha técnica. 2012 Full text (in our servers)
  6. FDA. Perindopril. Drug Summary. 2011 Full text (in our servers)

Total visits

9,773

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM